ANRS and CTN study shows ‘on-demand’ pre-exposure prophylaxis (PrEP)
taken before sex reduces risk for HIV among men who have sex
“This study extends the versatility of PrEP for real-world
conditions and adds another prevention tool along with
counseling and condoms,” says Dr. Cécile Tremblay, the Canadian
Principal Investigator of
Unlike other studies that tested the daily use of PrEP, ANRS
IPERGAY tested the intermittent or ‘on demand’ use of Truvada.
Participants randomized to the treatment arm, took two pills in
the 24-hour period before anticipated sexual intercourse and two
separate one-pill doses in the two days following sex.
The ANRS IPERGAY trial was run by the French national AIDS
research institute, ANRS, and began in France in February 2012
with the Professor Jean-Michel Molina as the Principal
Investigator. The CIHR Canadian HIV Trials Network (CTN) joined
as a Canadian site in 2013 and was led by Dr. Cécile Tremblay
(Centre hospitalier de l’Université de Montréal (CHUM). In
Canada, the study recruited 53 men who have sex with men (MSM)
into Phase I of the randomized study.
Following recent results of other studies (PROUD and iPrEx)
recommending the daily use of PrEP, the ANRS contacted the
IPERGAY trial data safety monitoring board (DSMB) for a review.
The DSMB examined the unblinded data and found a significant
difference in incidence between the treatment and placebo group
with a “very significant reduction” in the risk of HIV infection
in the PrEP group. The DSMB therefore recommended that all
IPERGAY participants should be offered ‘on demand’ Truvada.
The full results of the ANRS IPERGAY trial will be available in
early 2015. The study will continue with open-abel ‘on-demand’
Truvada for at least a year. It is important to ensure the
continued long-term benefit of ‘on demand’ PrEP and also assess
its long-term safety.
"The results of the ANRS IPERGAY trial will change prevention
guidelines,” says Dr. Aslam Anis, CTN National Director.
About the CIHR Canadian HIV Trials Network:
The CIHR Canadian HIV Trials Network (CTN) is funded by the
Canadian Institutes of Health Research (CIHR) and sponsored by
the University of British Columbia and St. Paul’s Hospital
(Providence Health Care). The CTN is a partnership of clinical
investigators, physicians, nurses, people living with HIV,
pharmaceutical manufacturers and others committed to developing
treatments, vaccines and a cure for HIV and related conditions
through the conduct of scientifically sound and ethical clinical
trials. The CTN is committed to the pursuits of scientific
excellence and ethical integrity in all undertakings. We are
also dedicated to working in partnership with the international
and national pharmaceutical industry, people living with HIV,
researchers and physicians.
Copyright (c) 2009-2014 The Valley Voice